Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Autoimmune Diseases
Biotech
Vor pays RemeGen $10M for long-acting autoimmune drug successor
Vor Bio is paying RemeGen $10 million upfront to add a long-acting autoimmune drug candidate to its BAFF/APRIL pipeline.
Nick Paul Taylor
Nov 12, 2026 10:16am
Kyverna abandons next-gen CAR-T once touted as miv-cel follow-up
Nov 12, 2026 10:06am
AbCellera becomes latest biotech to abandon OX40 drug
Nov 10, 2026 5:06am
T-Therapeutics raises $133M series B with Big Pharma backers
Nov 5, 2026 4:00am
Celltrion picks up another Kaigene antibody for up to $580.5M
Oct 22, 2026 10:22am
Pfizer makes 'business decision' to end trial of autoimmune drug
Oct 20, 2026 6:59am